Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is expected to release its quarterly earnings with an estimated EPS of $10.56 and revenue of approximately$3.78 billion.The company's stock has seen a significant increase of over 16%, with a current P/E ratio of approximately 17.Regeneron's financial stability is highlighted by a low debt-to-equity ratio of 0.087 and a strong current ratio of 4.06.Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a leading biotechnology company known for its innovative medicine ...